Over the first half of 2019, a staggering $170B has been pledged to biopharma buyout activities, an amount that exceeds the total deal spend of the last three years combined.
With the increasing complexity and frequency of biopharma M&A transactions, how do you ensure that synergy targets are met or exceeded? What are some of the key success factors, and what are some of the biggest ‘real-world’ pitfalls and watch-outs to address?
In this panel we will be exploring these topics with highly experienced “roll-up-the sleeves” executives who have succeeded in M&A where others have failed. Please send your questions in advance, as this engaging talk promises to offer tangible lessons learned and takeaways.